Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
What’s happening: An update on HIV drugs in India
Time to re-write or clarify the pre-grant opposition rules?
Pre-95 drugs are not patentable in India – or are they?
News on I-MAK Study on 2nd Line HIV drugs
What’s Happening: An Update on HIV Drug Patents
En Garde!
Bridges on the Dismissal of the Novartis Patent Challenge
The Economic Times -Efficacy
Abbott’s HIV drug, kaletra, faces pre grant opposition in India, Europe
Abbott Lab’s bid for anti-HIV drug patent to face stiff challenge